AstraZeneca

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Employees: 89.9K

Market Cap: $270.3B

Website: http://www.astrazeneca.co.uk

Introduction: AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Clinical Trials

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Phase 1

Recruiting

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: T-DXd
Biological: Durvalumab
Drug: Carboplatin
Drug: Rilvegostomig
Drug: Cisplatin
Drug: Volrustomig
Drug: Pemetrexed

First Posted Date: 2020-12-28

Last Posted Date: 2025-04-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 244

Registration Number: NCT04686305

Locations: 🇹🇷
Research Site, Bornova-Izmir, Turkey

Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone

Phase 4

Completed

Conditions: Hyperkalaemia
Heart Failure With Reduced Ejection Fraction

Interventions: Drug: Sodium zirconium cyclosilicate
Drug: Placebo
Other: Spironolactone

First Posted Date: 2020-12-21

Last Posted Date: 2024-08-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 366

Registration Number: NCT04676646

Locations: 🇬🇧
Research Site, Sheffield, United Kingdom

Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects

Phase 1

Completed

Conditions: Cancer

Interventions: Drug: AZD6094 (Savolitinib) film coated tablets 600 mg
Drug: [14C]-AZD6094 (Savolitinib) Solution for Infusion, 20 μg/mL (NMT 37.0 kBq/5 mL)
Drug: [14C] AZD6094 (Savolitinib) Oral Solution, 300 mg (NMT 4.1 MBq)

First Posted Date: 2020-12-19

Last Posted Date: 2021-01-26

Lead Sponsor: AstraZeneca

Target Recruit Count: 8

Registration Number: NCT04675021

Locations: 🇬🇧
Research Site, Ruddington, United Kingdom

A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee

Phase 2

Completed

Conditions: Painful Osteoarthritis of the Knee

Interventions: Drug: MEDI7352
Other: Placebo

First Posted Date: 2020-12-19

Last Posted Date: 2025-02-10

Lead Sponsor: AstraZeneca

Target Recruit Count: 345

Registration Number: NCT04675034

Locations: 🇬🇧
Research Site, Shipley, United Kingdom

Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Biological: Tezepelumab

First Posted Date: 2020-12-17

Last Posted Date: 2024-01-08

Lead Sponsor: AstraZeneca

Target Recruit Count: 18

Registration Number: NCT04673630

Locations: 🇬🇧
Research Site, London, United Kingdom

Observational Study of Durvalumab in Patients With Non-small-cell Lung Cancer in the United Kingdom

Completed

Conditions: Non-Small Cell Lung Cancer NSCLC

First Posted Date: 2020-12-14

Last Posted Date: 2023-10-02

Lead Sponsor: AstraZeneca

Target Recruit Count: 115

Registration Number: NCT04667312

Locations: 🇬🇧
East Kent Hospital, Canterbury, United Kingdom
🇬🇧
Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
🇬🇧
Velindre Hospital, Cardiff, United Kingdom

and more 7 locations

A Study to Investigate the Effect of Roxadustat Versus Recombinant Human Erythropoietin (rHuEPO) on Oral Iron Absorption in Chinese Patients With Anemia of Chronic Kidney Disease (CKD)

Phase 4

Completed

Conditions: Anemia of Chronic Kidney Disease

Interventions: Drug: Roxadustat
Drug: rHuEPO

First Posted Date: 2020-12-04

Last Posted Date: 2024-04-22

Lead Sponsor: AstraZeneca

Target Recruit Count: 25

Registration Number: NCT04655027

Locations: 🇨🇳
Research Site, Wuhan, China

Observational Retrospective Study on Clinical Outcomes of Patients Receiving Benralizumab in Spain.

Completed

Conditions: Severe Asthma

First Posted Date: 2020-12-02

Last Posted Date: 2022-08-19

Lead Sponsor: AstraZeneca

Target Recruit Count: 221

Registration Number: NCT04648839

Locations: 🇪🇸
Research Site, Madrid, Spain

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Phase 1

Recruiting

Conditions: Ovarian Cancer
Colorectal Cancer
Endometrial Cancer
Small Cell Lung Cancer Only in Module 5
Breast Cancer
Pancreatic Cancer
Prostate Cancer
Additional Indications Below for Module 4 and 5
Non-small Cell Lung Cancer
Bladder Cancer

Interventions: Drug: AZD5305
Drug: Paclitaxel
Drug: T- Dxd
Drug: Dato-DXd
Drug: Camizestrant
Drug: Carboplatin

First Posted Date: 2020-11-25

Last Posted Date: 2025-04-20

Lead Sponsor: AstraZeneca

Target Recruit Count: 804

Registration Number: NCT04644068

Locations: 🇬🇧
Research Site, Sutton, United Kingdom

Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.

Phase 3

Completed

Conditions: Carcinoma, Non- Small Cell Lung

Interventions: Drug: Durvalumab
Other: Placebo

First Posted Date: 2020-11-24

Last Posted Date: 2024-06-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 30

Registration Number: NCT04642469

Locations: 🇻🇳
Research Site, Hochiminh, Vietnam

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy